Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Curis' Shares Take Off as FDA Clears IND Application for Monoclonal Anti-VISTA Antibody

Curis Inc. shares are up more than 130% and established a new 52-week high price after reporting that the FDA cleared the company's IND Application for CI-8993, its monoclonal anti-VISTA antibody. Biotechnology company Curis Inc. (CRIS:NASDAQ) , which concentrates...
Streetwise Reports | June 11, 2020 |

Regeneron Shares Rise 10% on Advances in its Novel COVID-19 Antibody Program

Shares of Regeneron Pharmaceuticals rose to a new 52-week high price after the company reported it has identified hundreds of virus-neutralizing antibodies and plans to initiate large-scale manufacturing by mid-April of a multi-antibody therapy to treat coronavirus. ...
Streetwise Reports | March 18, 2020 |

Biotech Identifies Antibody with 100% SARS-CoV-2 Inhibition

The goal of Sorrento Therapeutics to develop a Covid-19 antibody cocktail, including its progress, next steps and market opportunity, is reviewed in a Dawson James report. In a May 26 research note, Dawson James analyst Jason Kolbert reported that Sorrento Therape...
Streetwise Reports | May 28, 2020 |

Antibody Developer Taken Out by Gilead at 'Hefty Premium'

The reasons Forty Seven attracted a buyer and its near-term catalysts are provided in a BTIG report. In a March 2 research note, BTIG analyst Robert Hazlett reported that Forty Seven Inc. (FTSV:NASDAQ) is being acquired by Gilead Sciences Inc. (GILD:NASDA...
Streetwise Reports | March 5, 2020 |

Vir Partners with Samsung Biologics on Large-Scale Manufacture of COVID-19 Antibody Treatment

Vir Biotechnology reported it has entered into an agreement with Samsung Biologics valued at $362 million for large-scale manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment. Though U.S. markets are closed for the Good Friday holiday, Samsung Biologics shar...
Streetwise Reports | April 13, 2020 |

Building a Better Covid-19 Antibody Test

ProMIS is harnessing its unique technology platform to develop a more error-free antibody test. Testing has been an Achilles heel of the coronavirus pandemic, but ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) has partnered with Dr. Hans Frykman and the ...
Streetwise Reports | May 7, 2020 |

Evotec, Memphasys, MorphoSys - Growth Industry Health

He who is healthy has many desires, he who is ill only one. Companies around the globe deal with diseases and special features of nature in order to treat or cure them. In addition to the widespread disease of cancer, there are also topics that are less talked about, but are a...
Mario Hose | January 20, 2020 |

Buzz on the Bullboards: COVID-19 Testing Plays

There are many investing plays that are attractive to serious investors and small-cap opportunists in the current market, but coronavirus movements take the cake. We’ve noted that each sector has its share of positive opportunities for both long-term and sh...
Omri Wallach | May 6, 2020 |

This stealth rally is about to explode into a huge bull market

It was a "stealth" rally... Over the first couple months of 2010, the U.S. stock market hovered around breakeven. Investors were too busy worrying about Greece's debt crisis, fourth-quarter earnings, and health care reform to notice what was happening over in my c...
Dr. George Huang | October 28, 2012 |

Could There Finally Be an Effective Treatment for Alzheimer's Disease?

ProMIS' preclinical treatment could possibly outshine Biogen's candidate. Finding an effective treatment for Alzheimer's disease has been elusive as many seemingly promising avenues of research did not prove out in clinical trials. Biogen Inc. (BIIB:NASDAQ) appeared...
Streetwise Reports | November 7, 2019 |
1 2 3 4 5 6